National Peroxide Limited company name approved its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27), alongside a significant downward revision of its audited FY26 net profit. The company reported a Q1FY27 net profit of ₹660.89 lakh on revenue from operations of ₹9,606.77 lakh. Simultaneously, the Board retrospectively restated FY26 profits from ₹1,103.71 lakh to ₹582.42 lakh after discovering an accounting error that understated raw material costs by ₹694.63 lakh due to incorrect ERP configuration for natural gas invoices.

The restatement was executed pursuant to Indian Accounting Standard (Ind AS) 8 – Accounting Policies, Changes in Accounting Estimates and Errors. M/s. Kalyaniwalla & Mistry LLP, the statutory auditors, issued a revised audit report with an unmodified opinion but included an Emphasis of Matter paragraph highlighting the correction. The Audit Committee reviewed and recommended the revised results on August 11, 2026, followed by Board approval on August 12, 2026. In accordance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company confirmed the issuance of the revised audit report.

For Q1FY27, revenue rose to ₹9,606.77 lakh from ₹8,568.29 lakh in the corresponding quarter of FY26. Total income stood at ₹9,819.38 lakh against total expenses of ₹8,936.15 lakh. Profit before tax was ₹883.23 lakh, resulting in a profit after tax of ₹660.89 lakh. Earnings per share (EPS) for the quarter were ₹11.50, compared to ₹16.06 in Q4FY26 and ₹1.55 in Q1FY26. The company continues to operate in a single segment focused on hydrogen peroxide manufacturing.

Financial Performance Overview

The Board reaffirmed its earlier recommendation of a final dividend of 70%, amounting to ₹7 per equity share of ₹10 each for FY26, subject to shareholder approval at the Annual General Meeting (AGM). However, citing the restated profits, the Board decided not to pursue the proposal for payment of commission to Non-Executive Directors.

Corporate Actions and Auditor Reappointment

The 6th AGM is scheduled for September 29, 2026, via video conference. The register of members will remain closed from September 23, 2026, to September 29, 2026, with the record date fixed at September 22, 2026. Based on the Audit Committee’s recommendation, the Board approved the reappointment of M/s. Kalyaniwalla & Mistry LLP as statutory auditors for a second term of five consecutive years, spanning from the conclusion of the 6th AGM to the 11th AGM, covering financial years up to March 31, 2031. This reappointment is disclosed under Regulation 30 of the Listing Regulations read with the SEBI Master Circular dated January 30, 2026.

What the Numbers Show

The restatement reveals a material correction in cost accounting where natural gas expenses were previously underreported. While revenue figures remained unchanged, the adjustment increased total expenses by ₹694.63 lakh, directly reducing pre-tax profits. Despite this correction, the company maintained profitability in FY26. Strong cash generation from operations, amounting to ₹3,423.99 lakh in FY26, underscores robust underlying operational efficiency, even as working capital management saw changes in trade payables due to the correction.

National Peroxide Ltd has deferred its Board Meeting scheduled for August 03, 2026, which was convened to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company informed the Bombay Stock Exchange on August 02, 2026, that the meeting has been postponed due to unavoidable circumstances. Investors seeking clarity on the firm’s performance in Q1FY26 must now wait for a revised date, which the company stated it would communicate to the stock exchange in due course as per regulatory requirements.

The deferment impacts the timeline for the release of quarterly financials, a key metric for market participants tracking the chemical manufacturer’s operational health. National Peroxide Limited, formerly known as NPL Chemicals Limited, had initially notified stakeholders of the meeting via an intimation dated July 29, 2026. The company did not specify the nature of the unavoidable circumstances leading to the postponement.

Regulatory Compliance and Trading Window

In compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company updated the exchange regarding the change in schedule. The original notice under the Listing Regulations had set August 03 as the date for the board to review the quarterly performance.

Consequent to the deferment, the trading window in respect of the company’s securities remains closed for all designated persons and their immediate relatives. This restriction, which began on July 01, 2026, will continue until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. This ensures that insiders do not trade while in possession of unpublished price-sensitive information regarding the Q1FY26 results.

Key Details

Akshay Satasiya, Company Secretary and Compliance Officer, signed the intimation filed with the BSE Limited. The company’s scrip code is 544205. No further details regarding the specific agenda items or expected outcomes of the deferred meeting were provided in the filing.